Finanzen von Neurogene Inc (NGNE)NGNENeurogene Inc

Evaluating the bottom line, Neurogene Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -45.32%, provide a clear picture of how effectively NGNE converts its operational activities into shareholder value.

In the context of the broader market, NGNE competes directly with industry leaders such as DRUG and MNPR. With a market capitalization of $723.21M, it holds a significant position in the sector. When comparing efficiency, NGNE's gross margin of N/A stands against DRUG's N/A and MNPR's N/A. Such benchmarking helps identify whether Neurogene Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 0% in recent quarters and a negative net income trend, with losses increasing to -34,488,000 USD in Q2 2026. Current assets are decreasing, indicating potential liquidity issues.